A randomized, double-blind, positive-controlled, multicenter study comparing the efficacy of carvedilol phosphate modified release formulation (COREG MR) and metoprolol succinate extended release (Toprol-XL) on the reduction of microalbuminuria [proteinuria] in patients with hypertension and microalbuminuria

Next Previous
Trial Profile

A randomized, double-blind, positive-controlled, multicenter study comparing the efficacy of carvedilol phosphate modified release formulation (COREG MR) and metoprolol succinate extended release (Toprol-XL) on the reduction of microalbuminuria [proteinuria] in patients with hypertension and microalbuminuria

Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs Carvedilol (Primary) ; Metoprolol
  • Indications Hypertension; Proteinuria
  • Focus Pharmacodynamics

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 20 Oct 2016 Status changed from completed to discontinued.
    • 01 Oct 2010 Actual end date (May 2006) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top